Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flutafuranol F 18 - Navidea Biopharmaceuticals

Drug Profile

Flutafuranol F 18 - Navidea Biopharmaceuticals

Alternative Names: [18F]-AZD4694; [18F]-NAV4694; AZD-4694; NAV-4694

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antidementias; Benzofurans; Fluorinated hydrocarbons; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Mild cognitive impairment

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 May 2018 Flutafuranol F 18 - Navidea Biopharmaceuticals is available for licensing as of 31 Dec 2017. https://www.sec.gov/Archives/edgar/data/810509/000143774918004756/navb20171231_10k.htm
  • 16 Apr 2018 Flutafuranol F 18 is still in phase II trials for Mild cognitive impairment in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top